EUVIMEDEUVIMED entdecken
Crossref

Cbl induced ubiquitination of HER2 mediate immune escape from HER2‐targeted CAR‐T

Yanqiu Yang, Qingqing Sun, Zhiping Deng, Wencong Shi, Hao Cheng

Journal of Biochemical and Molecular Toxicology · 2023-10 · 37 (10)

DOI: 10.1002/jbt.23446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 24.06.2023. Verfasst von Yanqiu Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasonography, The Fifth People's Hospital of Qinghai Province, Qinghai, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Proto-Oncogene Proteins c-cbl, Ubiquitination, Breast Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: The Shaanxi Provincial Health Commission Youth Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) with high HER2 expression has higher recurrence rate and worse prognosis, and its immunotherapy is promising. Based on the high expression of HER2, develop Chimeric Antigen Receptor T‐cell (CAR‐T) and PDL‐1 immunotherapy, and study the molecular pathways of related immune cells and recurrence. HER2‐CAR‐T cells were constructed using retroviruses, and their specific recognition and immune effects on HER2+ BC cells were verified by in vivo and in vitro experiments. PDL‐1 was used as adjuvant immunotherapy, knocking down PDL‐1 in tumor cells or dendritic cells, or depleted macrophages to study immune pathways. The negative regulation of HER2 by cbl was determined by IP, ubiquitination experiments, and segmented plasmids, elucidating the molecular mechanism of HER2+ BC recurrence after immunotherapy. HER2‐CAR‐T specifically recognizes HER2‐positive tumor cells and inhibits tumor growth in vivo and in vitro, and anti‐PDL1 treatment enhances the therapeutic effect of HER2‐CAR‐T on tumors. HER2‐CART therapy eradicated solid tumors after PDL1 knockdown in dendritic cells. Immunotherapy of relapsed tumors lost HER2 expression by upregulating cbl. HER2‐CAR‐T shows specific recognition of HER2+ cells and can mediate immune response therapy with the cooperation of PDL‐1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins c-cblUbiquitinationBreast NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveTumor EscapeHumansFemaleAnimalsMiceCell Line, TumorDendritic Cells

Stichwörter der Autor:innen

CAR-THER2PDL-1breast carcinomacbl

Substanzen

Erb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins c-cblERBB2 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Ultrasonography, The Fifth People's Hospital of Qinghai Province, Qinghai, China.
  • The Third Department of Convalescence, Lintong Rehabilitation and Recuperation Center, Xi'an, China.
  • Department of Breast Surgery, Shaanxi Cancer Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Shanxi, China.
  • Department of Ultrasonography, Shaanxi Cancer Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Förderung

  • The Shaanxi Provincial Health Commission Youth Project

Zitieren

APA

Yang, Y., Sun, Q., Deng, Z., Shi, W., & Cheng, H. (2023). Cbl induced ubiquitination of HER2 mediate immune escape from HER2‐targeted CAR‐T. Journal of Biochemical and Molecular Toxicology, 37(10). https://doi.org/10.1002/jbt.23446

Vancouver

Yang Y, Sun Q, Deng Z, Shi W, Cheng H. Cbl induced ubiquitination of HER2 mediate immune escape from HER2‐targeted CAR‐T. Journal of Biochemical and Molecular Toxicology. 2023;37(10). doi:10.1002/jbt.23446

BibTeX
@article{Yang2023,
  author = {Yang, Yanqiu and Sun, Qingqing and Deng, Zhiping and Shi, Wencong and Cheng, Hao},
  title = {Cbl induced ubiquitination of HER2 mediate immune escape from HER2‐targeted CAR‐T},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2023},
  volume = {37},
  number = {10},
  doi = {10.1002/jbt.23446}
}
Kostenlos starten →